Search Results - Salwender, H.J.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY‐DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG‐MM5 TRIAL

    PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY‐DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG‐MM5 T... by Mai, E.K., Miah, K., Merz, M., Dürig, J., Scheid, C., Weisel, K.C., Kunz, C., Bertsch, U., Munder, M., Lindemann, H.‐W., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M.S., Blau, I.W., Hänel, M., Benner, A., Salwender, H.J., Goldschmidt, H.

    Published in HemaSphere
    Request full text
    Article
    Save to List
    Saved in:
  2. 2
    About the Threshold for Fatal or Potentially Fatal Injuries in Car-to-Car Side Collisions - A Comparison Between Real Accidents and PMHS-Tests

    About the Threshold for Fatal or Potentially Fatal Injuries in Car-to-Car Side Collisions - A Comparison Between Real Accidents and PMHS-Tests by Miltner, E, Kallieris, D, Wiedmann, K.P, Leutwein, B, Hepp, H.-P, Fischer, R, Salwender, H.J, Frobenius, H

    Request full text
    Report
    Save to List
    Saved in:
  3. 3
    Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

    Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma by Lokhorst, Henk M, Schmidt-Wolf, Ingo, Sonneveld, Pieter, van der Holt, Bronno, Martin, Hans, Barge, Rene, Bertsch, Uta, Schlenzka, Jana, Bos, Gerard M.J, Croockewit, Sandra, Zweegman, Sonja, Breitkreutz, Iris, Joosten, Peter, Scheid, Christof, van Marwijk-Kooy, Marinus, Salwender, Hans-Juergen, van Oers, Marinus H.J, Schaafsma, Ron, Naumann, Ralph, Sinnige, Harm, Blau, Igor, Delforge, Michel, de Weerdt, Okke, Wijermans, Pierre, Wittebol, Shulamiet, Duersen, Ulrich, Vellenga, Edo, Goldschmidt, Hartmut, for Dutch-Belgian HOVON and German GMMG

    Published in Haematologica (Roma)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years

    HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years by Goldschmidt, Hartmut, Sonneveld, Pieter, Breitkreuz, Iris, van der Holt, Bronno, Benner, Axel, Barge, Renee M.Y., Salwender, Hans, Bos, Gerard M.J., Glasmacher, Axel, Raymakers, Reinier, Scheid, Christof, Huijgens, Peter C., Naumann, Ralph, van Oers, Marinus H.J., Hänel, Annette, Vellenga, Edo, Martin, Hans, Wijermans, Pierre W., Ho, Anthony D., Westveer, Petra H.M., Verhoef, Gregor E.G., Mazitschek, Uta, Lokhorst, Henk M.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: